Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Investing Activities (2016 - 2025)

CorMedix's Cash from Investing Activities history spans 13 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 1185.0% year-over-year to $3.3 million; the TTM value through Dec 2025 reached -$308.4 million, down 1552.73%, while the annual FY2025 figure was -$308.4 million, 1552.73% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $3.3 million at CorMedix, up from -$291.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $8.9 million in Q1 2024 and bottomed at -$291.3 million in Q3 2025.
  • The 5-year median for Cash from Investing Activities is -$208275.0 (2021), against an average of -$18.5 million.
  • The largest YoY upside for Cash from Investing Activities was 1185.0% in 2025 against a maximum downside of 4708.5% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$7.1 million in 2021, then skyrocketed by 99.97% to -$1861.0 in 2022, then tumbled by 789088.88% to -$14.7 million in 2023, then soared by 97.93% to -$303874.0 in 2024, then surged by 1185.0% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Cash from Investing Activities are $3.3 million (Q4 2025), -$291.3 million (Q3 2025), and -$20.2 million (Q2 2025).